Glucocorticoid-based combination therapy for chronic lymphotic leukemia: New tricks for an old dog

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1843-1845

  Pettitt, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CAM PRED; DEXAMETHASONE; GLUCOCORTICOID; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PREDNISOLONE; PROTEIN P53; RITUXIMAB; UNCLASSIFIED DRUG;

ADD ON THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; HUMAN; HYPERGLYCEMIA; INFECTION; MONOTHERAPY; MOOD DISORDER; NOTE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; GLUCOCORTICOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TREATMENT OUTCOME;

EID: 55049130775     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802455883     Document Type: Note

References (9)

1. Bosanquet, A. G., McCann, S. R., Crotty, G. M., Mills, M. J. and Catovsky, D. (1995) Methylprednisolone in advanced chronic lymphocytic leukaemia: Rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol, 93, pp. 73-79.
2. Thornton, P. D., Hamblin, M., Treleaven, J. G., Matutes, E., Lakhani, A. K. and Catovsky, D. (1999) High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma, 34, pp. 167-170.
3. Thornton, P. D., Matutes, E., Bosanquet, A. G., Lakhani, A. K., Grech, H. Ropner, J. E. et al. (2003) High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol, 82, pp. 759-765.
4. Castro, J. E., Sandoval-Sus, J. D., Bole, J., Rassenti, L. and Kipps, T. J. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia
5. Castro, J. E., Bole, J. E., Prada, C. E., Loria, O. and Kipps, T. J. (2005) Rituximab and high-dose methylprednisolone as a first-line treatment for patients with chronic lymphocytic leukemia. Blood, 106, p. 2969.
6. Bowen, D. A., Call, T. G., Jenkins, G. D., Zent, C. S., Schwager, S. M. Van Dyke, D. L. et al. (2007) Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavourable cytogenetic features. Leuk Lymphoma, 48, pp. 2412-2417.
7. Dungarwalla, M., Evans, S. O., Riley, U., Catovsky, D., Dearden, C. E. and Matutes, E. (2008) High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica, 93, pp. 475-476.
8. Quinn, J., Sajir, M., Chipperfield, K., Treacy, M., D'Sa, S. and Nathwani, A. (2008) Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukaemia. Leuk Lymphoma, 49, pp. 1995-1998.
9. Pettitt, A. R., Matutes, E. and Oscier, D. (2006) Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia, 20, pp. 1441-1415.